Major study launches to uncover heart risks of hormone therapy for transgender individuals
NCT ID NCT07128771
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study follows 450 people with gender incongruence who are starting or continuing gender-affirming hormone therapy. Researchers will use heart scans, blood tests, and quality-of-life surveys over several years to see if the therapy changes heart structure or raises cardiovascular risk. The goal is to provide clear information for patients, families, and doctors to make informed decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE (CVD) RISK FACTORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oslo University Hospital
Oslo, Oslo, Norway
Conditions
Explore the condition pages connected to this study.